Multiple system atrophy: Prognostic factors in the "MSA- Aquitaine" cohort;Atrophie multisystématisée: Survie et facteurs pronostiques dans la cohorte «MSA-Aquitaine»

Revue Neurologique

Volumn 163, Issue 1, 2007, Pages 54-65

  Krim, E ^a   Yekhlef, F ^a   Chrysostome, V ^a,b   Ghorayeb, I ^a   Tison, F ^a,c  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

Cohort study; Multiple System Atrophy; Natural history; Prognostic factors; Survival

Indexed keywords

LEVODOPA;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL EXAMINATION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DYSPHAGIA; FEMALE; FOLLOW UP; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; PREDICTION; PROGNOSIS; SEX RATIO; SHY DRAGER SYNDROME; STRIDOR; SURVIVAL RATE; TELEPHONE;

EID: 33847116838     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0035-3787(07)90355-0     Document Type: Article

References (52)

1. ARVANITAKIS Z, WILSON RS, SCHNEIDER JA, BIENIAS JL, EVANS DA, BENNETT DA. (2004). Diabetes mellitus and progression of rigidity and gait disturbance in older persons. Neurology, 63: 996-1001.
2. BAK TH, CRAWFORD LM, HEARN VC, MATHURANATH PS, HODGES JR. (2005). Subcortical dementia revisited: similarities and differences in cognitive function between progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA). Neurocase, 11: 268-273.
3. BENRUD-LARSON LM, SANDRONI P, SCHRAG A, LOW PA. (2005). Depressive symptoms and life satisfaction in patients with multiple system atrophy. Mov Disord, 20: 951-957.
4. BEN-SHLOMO Y, WENNING GK, TISON F, QUINN NP. (1997). Survival of patients with pathologically proven multiple system atrophy. A meta-analysis. Neurology, 48: 384-393.
5. BERGER K, BRETELER MMB, HELMER C et al. (2000). Prognosis with Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurology, 54: S24-S27.
6. BOURDEL-MARCHASSON I, DUBROCA B, DECAMPS A, RICHARD-HARSTON S, EMERIAU JP, DARTIGUES JF. (1998). Five-year mortality in elderly french subjects from the PAQUID epidemiological survey: the burden of diabetes. Diabet Med, 15: 830-835.
7. BOWER JH, MARAGANORE DM, MC DONNEL SK, ROCCA WA. (1997). Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted Country, Minnesota, 1976 to 1990. Neurology, 49: 1284-1288.
8. BURN DJ, LEES AJ. (2002). Progressive supranuclear palsy: where are we now ? Lancet Neurol, 1: 359-369.
9. CHRYSOSTOME V, TISON F. (2003). Épidé miologie des syndromes parkinsoniens. Rev Neurol (Paris), 159: 343-352.
10. CHRYSOSTOME V, TISON F, YEKHLEF F, SOURGEN C, BALDI I, DARTIGUES JF. (2004). Epidemiology of multiple system atrophy: a prevalence and pilot risk factor study in Aquitaine, France. Neuroepidemiology, 23: 201-208.
11. FUHRER R, ROUILLON F. (1989). La version française de l'échelle CES-D. Description et traduction de l'échelle d'autoévaluation. Psychiatr Psychobiol, 4: 163-166.
12. GALVIN JE, LEE VMY, TROJANOWSKI JQ. (2001). Synucleinopathies. Clinical and pathological implications. Arch Neurol, 58: 186-190.
13. GESER F, WENNING GK, SEPPI K et al. (2005). Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). Mov Disord, article online in advance of print.
14. GHORAYEB I, YEKHLEF F, CHRYSOSTOME V, BALESTRE E, BIOULAC B, TISON F. (2002). Sleep disorders and their determinants in multiple system atrophy. J Neurol Neurosurg Psychiatry, 72: 798-800.
15. GHORAYEB I, BIOULAC B, TISON F. (2004). Relationship between stridor and sleep apnoea syndrome: is it as simple as that? J Neurol Neurosurg Psychiatry, 75: 512-513.
16. GILMAN S, LOW PA, QUINN NP et al. (1999). Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sc, 163: 94-98.
17. GILMAN S, LITTLE R, JOHANNS J et al. (2000). Evolution of sporadic olivopontocerebellar atrophy into Multiple system atrophy. Neurology, 55: 527-532.
18. GU K, COWIE CC, HARRIS MI. (1998). Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care, 21: 1138-1145.
19. HOEHN MM, YAHR MD. (1967). Parkinsonism: onset, progression and mortality. Neurology, 17: 427-442.
20. HONNORAT J, SAIZ A, GIOMETTO B et al. (2001). Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol, 58: 225-230.
21. HUGUIER M, FLAHAULT A. (2003). L'évaluation d'un pronostic. Dans Biostatistiques au quotidien. Paris, Elsevier.
22. IRANZO A, SANTAMARIA J, TOLOSA E et al. (2004). Long-term effect of CPAP in the treatment of noctural stridor in multiple system atrophy. Neurology, 63: 930-932.
23. KLOCKGETHER T, LÜDTKE R, KRAMER B et al. (1998). The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain, 121: 589-600.
24. KRYSTKOWIAK P. (2000). Les échelles d'évaluations dans la maladie de Parkinson. Rev Neurol (Paris), 156: S2b52-S2b62.
25. MABUCHI N, HIRAYAMA M, KOIKE H et al. (2005). Progression and prognosis in pure autonomic failure (PAF): comparison with multiple system atrophy. J Neurol Neurosurg Psychiatry, 76: 947-952.
26. MÜLLER J, WENNING GK, VERNY M et al. (2001). Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Arch Neurol, 58: 259-264.
27. OSAKI Y, WENNING GK, DANIEL SE et al. (2002). Do published criteria improve clinical diagnostic accuracy in multiple system atrophy? Neurology, 59: 1486-1491.
28. PAPP MI, LANTOS PL. (1994). The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain, 117: 235-243.
29. QUINN NP. (1989). Multiple system atrophy. The nature of the beast. J Neurol Neurosurg Psychiatry, 32: 78-89.
30. QUINN NP. (1995). Parkinsonism recognition and differential diagnosis. Br Med J, 310: 447-452.
31. QUINN NP. (2005). How to diagnose multiple system atrophy. Mov Disord, 20: S5-S10.
32. SAITO Y, MATSUOKA Y, TAKAHASHI A, OHNO Y. (1994). Survival of patients with multiple system atrophy. Internal Medicine, 33: 321-325.
33. SCHRAG A, BEN-SHLOMO Y, QUINN NP. (1999). Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet, 354: 1771-1775.
34. SCHULZ JB, KLOCKGETHER T, PETERSEN D et al. (1994). Multiple system atrophy: natural history, MRI morphology and dopamine receptor imaging with I123 BZM-SPECT. J Neurol Neurosurg Psychiatry, 57: 1047-1056.
35. SEPPI K, YEKHLEF F, DIEM A et al. (2005). Progression of parkinsonism in multiple system atrophy. J Neurol, 252: 91-96.
36. SILBER MH, LEVINE S. (2000). Stridor and death in multiple system atrophy. Mov Disord, 15: 699-704.
37. TESTA D, FILIPPINI G, FARINOTTI M. (1996). Survival in multiple system atrophy: a study of pronostic factors in 59 cases. J Neurol, 243: 401-404.
38. TESTA D, MONZA D, FERRARINI M. (2001). Comparison of natural history of progressive supranuclear palsy and multiple system atrophy. J Neurol Sci, 22: 247-251.
39. TISON F, WENNING GK, VOLONTE MA. (1996). Pain in Multiple System Atrophy. J Neurol, 243: 153-156.
40. TISON F, YEKHLEF F, CHRYSOSTOME V, SOURGEN C. (2000). Prevalence of Multiple System Atrophy. Lancet, 355: 495-496.
41. TISON F, YEKHLEF F, CHRYSOSTOME V et al. (2002a) Parkinsonism in multiple system atrophy: natural history severity (UPDRS-III) and disability assessment compared with Parkinson's disease. Mov Disord, 17: 701-709.
42. TISON F, YEKHLEF F, BALESTRE E et al. (2002b). Application of the International Cooperative Ataxia Rating Scale in multiple system atrophy. Mov Disord, 17: 1248-1254.
43. VANACORE N, BONIFATI V, FABBRINI G et al. (2001). Epidemiology of multiple system atrophy. ESGAP consortium. European study group of atypical parkinsonisms. Neurol Sci, 22: 97-99.
44. WATANABE H, SAITO Y, TERAO S et al. (2002). Progression and pronosis in multiple system atrophy. An analysis of 230 Japanese patients. Brain, 125: 1070-1083.
45. WENNING GK, WAGNER S, DANIEL S, QUINN NP. (1993). Multiple system atrophy: sporadic or familial? Lancet, 342: 681.
46. WENNING GK, BEN-SHLOMO Y, MAGAHAES M, DANIEL SE, QUINN NP. (1994). Clinical features and natural history of Multiple System Atrophy. Analysis of 100 cases. Brain, 117: 835-845.
47. WENNING GK, BEN-SHLOMO Y, MAGALHAES, DANIEL SE, QUINN NP. (1995). Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry, 58: 160-166.
48. WENNING GK, TISON F, BEN-SHLOMO Y, DANIEL SE, QUINN NP. (1997). Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord, 12: 133-147.
49. WENNING GK, GESER F, STAMPFER-K OUNTCHEV, TISON F. (2003). Multiple system atrophy: an update. Mov Disord, 18: S34-S42.
50. WENNING GK, COLOSIMO C, GESER F, POEWE W. (2004a). Multiple system atrophy. Lancet Neurol, 3: 93-103.
51. WENNING GK, TISON F, SEPPI K et al. (2004b). Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord, 19: 1391-1402.
52. WENNING GK, GESER F, POEWE W. (2005). Therapeutic strategies in multiple system atrophy. Mov Disord, 20: S67-S76.